Halifax, Nova Scotia, November 08, 2018 – Sona Nanotech Inc. (CSE: SONA) has engaged the services of a leading expert in gold and nanotechnology to help develop its business proposition in Europe.
UK-based consultant Trevor Keel has a degree in chemistry from the University of Kent, a PhD in nanotechnology from the University of Nottingham and a master’s degree in management from University College London.
His previous roles have included principal chemist at GlaxoSmithKline, one of the world’s largest pharmaceutical companies, and head of technology for the World Gold Council, the market development organisation for the gold industry.
Dr Keel will provide business development services to Sona Nanotech Inc. in the UK and Europe, using his wide network of contacts to develop new business opportunities, collaborations and projects in the lateral flow market utilizing Sona’s range of unique gold nanorods.
Darren Rowles, Sona’s CEO and president, said: “We are privileged to have secured the services of Trevor Keel, who is a well-known and respected figure in the fields of gold and nanotechnology.
Trevor’s technical knowledge across the chemical and healthcare sectors is unrivalled, and this, combined with his experience of developing strategic relationships at the highest level, will be invaluable as we look to grow our business in the highly competitive markets of the UK, Europe and beyond.”
Trevor Keel said: “I am delighted to be working with such an ambitious, dynamic and innovative company. I have followed Sona Nanotech’s recent growth and breakthroughs with keen interest, and it is clear to see that this is a company with an exciting future in the lateral flow sector. Sona’s gold nanorod technology is truly unique in this market, and I know that there will be huge interest in its products and services from many European-based companies. I can’t wait to get started.”
Dr Keel’s first overseas trip for Sona will be to represent the company at MEDICA, the world’s leading trade fair for the medical industry, in Dusseldorf, Germany next week.
Anyone wishing to discuss Sona’s products and services at MEDICA can contact Darren Rowles on (902) 442-7192
About Sona Nanotech Inc.
Sona Nanotech Inc. is a nanotechnology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market.
Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.
Sona is a publicly listed company on the Canadian Securities Exchange existing under the laws of Nova Scotia, with its operations in Nova Scotia.
For More Information
For more information about Sona, please contact:
President and Chief Executive Officer
Telephone: (902) 442-7192
Email: Darren Rowles firstname.lastname@example.org
FORWARD LOOKING INFORMATION
This press release
contains forward-looking statements and information that are based on the
beliefs of management and reflect the Company’s current expectations. When used
in this press release, the words “estimate”, “project”, “belief”,
“anticipate”, “intend”, “expect”,
“plan”, “predict”, “may” or “should”
and the negative of these words or such variations thereon or comparable
terminology are intended to identify forward-looking statements and information.
The forward-looking statements and information in this press release includes
information relating to the Amalgamation (including the structure of the
Amalgamation), the Amalgamation (including shareholder approval, shareholder
support, and other terms), the Private Placement (including its completion and
the use of proceeds from the Private Placement), the directors and management
of the resulting issuer upon completion of the Amalgamation, and the
implementation of Sona’s business plan. Such statements and information reflect
the current view of the Company with respect to risks and uncertainties that
may cause actual results to differ materially from those contemplated in those
forward-looking statements and information.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with the completion of the Amalgamation and matters relating thereto; and risks associated with the marketing and sale of securities, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors, and the volatility of the Company’s common share price and volume. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.
There are a number
of important factors that could cause the Company’s actual results to differ
materially from those indicated or implied by forward-looking statements and
information. Such factors include, among others, risks related to Sona’s
proposed business, such as failure of the business strategy and government
regulation; risks related to Sona’s operations, such as additional financing
requirements and access to capital, reliance on key and qualified personnel,
insurance, competition, intellectual property and reliable supply chains; risks
related to Sona and its business generally, such as infringement of
intellectual property rights and conflicts of interest. The Company cautions
that the foregoing list of material factors is not exhaustive. When relying on
the Company’s forward-looking statements and information to make decisions,
investors and others should carefully consider the foregoing factors and other
uncertainties and potential events. The Company has assumed a certain progression,
which may not be realized. It has also assumed that the material factors
referred to in the previous paragraph will not cause such forward-looking
statements and information to differ materially from actual results or events.
However, the list of these factors is not exhaustive and is subject to change
and there can be no assurance that such assumptions will reflect the actual
outcome of such items or factors. While the Company may elect to, it does not
undertake to update this information at any particular time.
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR DISSEMINATION IN THE UNITED STATES